Sitemap
Pages
- Ampersand Approach
- Beyond Borders: A Disciplined Approach to Successful Global Expansion
- Contact Us
- Contract Manufacturing
- Cookie Policy
- Core Values
- Forging Leaders
- Home
- Industry Insights
- Laboratory Products
- Laboratory Services
- News
- Our Team
- Pharma Services
- Portfolio
- Privacy Notice
- Sitemap
- Specialty Products
- Terms and Conditions
Case Studies
Team Members
- Cole S. Aldrich
- Natalia C. Anderson
- David Q. Anderson
- Stuart A. Auerbach
- Kristine C. Austin
- Mark R. Bamforth
- Stefan Beyer
- Benoit P. Bouche
- Trent Carrier
- Steven J. Chang
- Richard A. Charpie
- Justin K. Choi
- Olivia M. Ciano
- Marina Pellón-Consunji
- Alison J. Crump
- Steven M. Dale
- Emanuele M. Delfino
- Henry Dubina
- Melanie M. Fan
- Steve Favaloro
- Nicolas S. Gianelli
- Julie F. Giles
- Aditya V. Goel
- Neil Gramopadhye
- Herb H. Hooper
- Thomas de Jager
- Maxwell R. Keeley
- Hidde Van Kerckhoven
- Eric B. Lev
- Peter Li
- Gregory W. Magoon
- Nicole R. Manning
- Alex J. Marotto
- Laurence R. McCarthy
- Arya Mehrabanzad
- Jenna N. Melvin
- Peter K. Messervy
- Matthew A. Munfakh
- Susan B. Murphy
- David Newble
- Dana L. Niles
- Matthew R. Norton
- David J. Parker
- David B. Patteson
- Matt Perry
- Jean Qiu
- Jay S. Ray
- Mario J. Reto
- Jessica Q. Rong
- Dean D. Schauer
- Ouren T. Schipperus
- Thomas Schweins
- Daniel Spasic
- Robert E. Sullivan
- Geoffrey P. Teillon
- Kathleen P. Toomey
- Léonard H. Vieilly
- Trevor L. Wahlbrink
- Patrick D. Walsh
- David Weber
- Frank R. Witney
News
- Gannet BioChem Achieves Science Based Targets initiative (SBTi) Validation for Near-Term Climate Commitments
- P95 and Julius Clinical Merge to Form Global, Science-Led CRO Delivering Integrated Clinical Development and Real-World Evidence
- Vantage MedTech Appoints Carlo W. Colesanti as President and Chief Executive Officer; Jim Bartel to Serve as Chief Commercial Officer; Randy Barko Named Executive Chairman of the Board
- Ampersand Capital Partners Named to Inc.’s 2025 List of Founder-Friendly Investors for Fourth Consecutive Year
- Life Sciences Innovator Dr. Art Tipton Joins Gannet BioChem Board; Company to Attend PODD 2025
- Julius Clinical Welcomes Bassem Saleh as Chief Executive Officer
- Ampersand Capital Partners Expands Global Presence with London Office, Appoints Matthew Norton as General Partner
- Ampersand Capital Partners Named a Top Private Equity Firm of 2025 by GrowthCap
- Ampersand Capital Partners Invests in CurTec, a Global Leader in Pharma & Specialty Chemicals Bulk Packaging
- VIVEbiotech Appoints Patricio Massera as President
- Ampersand Capital Partners Ranked #1 Globally for Growth Capital Private Equity Performance for the Third Consecutive Year by HEC Paris–Dow Jones
- Julius Clinical and Peachtree BioResearch Solutions Merge to Form a Fully Integrated Global CRO with Increased CNS Capabilities
- David Anderson Named a Top Healthcare Investor of 2025 by GrowthCap
- Gannet BioChem Welcomes Dr. Harry Rathore as Board Member
- Lexington Medical Secures Growth Investment from Ampersand Capital Partners
- Gannet BioChem Names Nicholas Shackley as Chief Executive Officer, Announces Leadership Team Expansion
- Julius Clinical Strengthens its European Capabilities by Expanding Operations in Poland
- GrowthCap Names Ampersand Capital Partners a Top Growth Equity Firm of 2024
- Avid Bioservices Poised for Significant Growth with New Partners GHO Capital and Ampersand Capital Partners
- Precision Coating, a Katahdin Company, Acquired by Integer
- MedPharm Appoints Bill Humphries as Chief Executive Officer to Lead Next Phase of Strategic Growth
- Canyon Lab Announces Strategic Acquisition of iuvo BioScience’s Lab Services and Consulting Businesses to Expand End-to-End Development Solutions
- NanoImaging Services Acquires Proteos, Enhancing Integrated Protein Sciences and Structure-Based Discovery Capabilities
- Ampersand Capital Partners 2024 Year in Review
- VIVEbiotech Secures Growth Investment from Ampersand Capital Partners to Expand Lentiviral Vector Development and Manufacturing Capabilities
- Ampersand Capital Partners Completes Acquisition of Nektar Therapeutics’ PEG Reagent Manufacturing Business, Launching Newly Branded Gannet BioChem
- Avid Bioservices to be Acquired by GHO Capital Partners and Ampersand Capital Partners in $1.1 Billion Transaction
- Biosynth Names Matt Gunnison as CEO, Kieran Murphy Appointed as Chairman
- Nektar Announces Definitive Agreement with Ampersand Capital Partners to Sell Its Commercial PEGylation Reagent Manufacturing Business in Alabama
- Ampersand Capital Partners Named to Inc.’s 2024 List of Founder-Friendly-Investors
- Resolian Appoints Rob Stachlewitz as CEO, Honggang Bi as Chairman of the Board, and Pat Bennett as Chief Business Officer and President of Scientific Affairs
- MedPharm Announces Board Expansion with Appointment of Industry Veteran Eric Evans
- P95 Acquires Assign DMB, Expanding Data Management and Biostatistics Services
- Leinco Technologies Inc. Acquires QED Biosciences, Leading Provider of Antibodies, Related Reagents, and Development Services
- Ampersand Capital Partners Named a Top Private Equity Firm of 2024 by GrowthCap
- Phosphorex Welcomes NOF CORPORATION as Shareholder and Strategic Partner
- P95 Welcomes Laurence De Moerlooze as Chief Medical Officer to Oversee Clinical and Epidemiology Operations
- MedPharm, Ltd. and Tergus Pharma Merger Forms Topical and Transdermal CDMO Leader
- P95 Acquires 4Clinics to Expand Global CRO Services, Strengthen Position as Market Leader
- Mark Dearden Named Chief Executive Officer of Specac, Ltd
- Genezen to Aquire uniQure’s Commercial Gene Therapy Manufacturing Operations in Lexington, MA
- Ampersand Capital Partners Named Top Performing Private Equity Fund Manager in the Americas by Preqin for Second Year in a Row
- Ampersand Capital Partners Ranks #1 for Growth Capital Private Equity Performance by HEC Paris-DowJones
- Phosphorex and NOF CORPORATION Collaborate to Supply Lipid Nanoparticle Formulations using NOF’s Proprietary Ionizable Lipid, COATSOME SS Series
- Jim Bartel Named Chief Executive Officer of Vantage MedTech
- P95’s Journey From Epidemiology Consulting to Comprehensive CRO
- Specac, Ltd Acquires Harrick Scientific
- Ampersand Capital Partners Acquires Biologos
- Ampersand Capital Partners Acquires Specac, Ltd.
- MedPharm Welcomes New Board Members, Appoints Industry Veteran Patrick Walsh as Executive Chairman
- David Bruning Named Chief Executive Officer of StageBio
- iuvo BioScience Acquires Promedica International to Expand Ophthalmic Clinical CRO Services
- MedPharm, Ltd. Appoints Lynn Allen as Chief Executive Officer
- NanoImaging Services Appoints John Rigg as Chief Executive Officer
- ALPCO Announces the Commercial Launch of its FDA 510(k) Cleared Calprotectin Immunoturbidimetric Assay
- Julius Clinical Research Receives Growth Investment from Ampersand Capital Partners
- New Capital Strengthens ProtaGene’s Advanced Analytical Leadership in the Biologics and Cell and Gene Therapy Markets
- Ampersand Capital Partners Named to Inc.’s 2023 List of Founder-Friendly-Investors
- Genezen Secures $18.5 Million in Growth Equity to Expand Viral Vector Development and Manufacturing Capabilities
- Resolian Acquires China-Based Bioanalytical CRO Denali Medpharma
- P95, A Leading Vaccine-Focused CRO, Merges with South Africa-based CRO OnQ Research
- GeneProof Announces Expansion of its IVDR-Certified PCR Portfolio
- Sterling Medical Devices and RBC Medical Innovations Rebrand as Vantage MedTech
- NanoImagine Services Sets New Standards as the First CGMP Compliant Cryo-TEM Lab in North America
- Preqin Ranks Ampersand Capital Partners as the Top Performing Private Equity Fund Manager and Top Performing Growth Fund Manager in the Americas
- Biosynth Expands Capabilities with Acquisition of celares, Experts in Bioconjugation and Specialty Polymers
- NanoImaging Services Receives Growth Equity Investment from Ampersand Capital Partners
- Alcami Announces CEO Transition
- Ampersand Capital Partners Ranked #1 on the 2022 HEC-DowJones Growth Capital Private Equity Performance Ranking
- Alliance Pharma and Drug Development Solutions Are Now Resolian
- Precision Coating Expands Surface Technology Offering with the Acquisition of Providence Texture
- P95 BV and Ampersand Capital Partners Join Forces to Establish First in Class Vaccine CRO
- Trinity Biotech Announces the $30 Million Sale of its Life Sciences Supply Business to Biosynth
- Thermo Fisher Partners with ALPCO-GeneProof to Broaden Their CE-IVD Molecular Assay Portfolio
- AnaBios Acquires Cell Systems, Expands Human Cell Portfolio for Drug Discovery
- iuvo BioScience Hires Industry Executive to Lead Commercial Organization
- ALPCO-GeneProof Appoints Erik M. Allen as Chief Executive Officer
- Genezen Announces the Appointment of Steven J. Favaloro as Chief Executive Officer to Support Next Phase of Growth
- Ampersand Portfolio Company Sterling Medical Devices Recapitalizes RBC Medical Innovations, Merges Entities
- Ampersand Capital Partners’ Marina Pellón-Consunji Recognized by GrowthCap as a 2022 Top 40 under 40 Growth Investor
- GHO Capital and The Vistria Group Complete Acquisition of Leading CDMO Alcami Corporation
- Alliance Pharma Opens State-of-the-Art Bioanalytical Laboratory in Brisbane
- Alcami Builds cGMP Biostorage Facility in North Carolina
- GHO Capital and The Vistria Group to acquire Alcami, a leading high growth CDMO, from Madison Dearborn Partners and Ampersand Capital Partners
- Ampersand Capital Partners Named in Inc.’s 2022 List of Founder-Friendly Investors
- iuvo BioScience to be Acquired by Ampersand Capital Partners
- Phosphorex Appoints Jarlath Keating as Chief Executive Officer
- Ampersand partners with Permira and ADIA to combine BPL and Kedrion
- Spatial Biology CRO Flagship Biosciences Acquires Pharma Services Business from Interpace Biosciences
- Dr. Glenn Haifer and Ampersand Capital Partners Acquire Australian Biologics CDMO Luina Bio, Rebranding Company as AcuraBio
- Phosphorex to Establish cGMP Manufacturing for Lipid Nanoparticles with Growth Capital from Ampersand
- Ampersand Closes Oversubscribed Fund at $1.2 Billion Hard Cap
- Ampersand Portfolio Company U.S. Alliance Pharma Acquires U.K.-based LGC’s Drug Development Solutions (DDS) Business
- Ampersand Capital Partners Invests in Sterling Medical Devices
- AnaBios Closes Financing with Ampersand Capital Partners
- Vernal Biosciences Raises $21 Million to Accelerate mRNA Manufacturing Growth
- Ampersand-backed Alliance Pharma to acquire LGC’s Drug Development Solutions Business (“DDS”) and welcomes KKR as joint shareholder
- American Laboratory Products Company Merges with GeneProof
- Ampersand Capital Partners Invests in Syft Technologies, Leading SIFT-MS Solutions Provider
- Alliance Pharma Appoints Patrick Bennett as Chief Executive Officer
- Ampersand Investment Opportunity: Syft Technologies
- Ampersand Invests Alongside KKR in Biosynth Carbosynth and Simultaneously Merges in vivitide
- BioEcho Life Sciences Receives Growth Equity Investment from Ampersand Capital Partners
- Recipharm acquires Arranta Bio, a CDMO leader in advanced therapy medicinal products (ATMPs), to expand its biologics offering in the US
- Vibalogics Acquired by Top Global CDMO Recipharm AB
- Confluent Medical Announces Closing of Majority Investment From TPG
- Analytical Service Leaders in Biopharmaceutical and Gene Therapy Development Unify Operations and Re-brand as ProtaGene
- Ampersand Announces Sale of Nexelis
- Confluent Medical Announces Significant Strategic Investment From TPG
- Ampersand Completes Sale of Adaptas Solutions to IMI plc
- Alcami Announces the Acquisition of Masy BioServices
- Martijn G. Mulder: In Memoriam
- ANI Pharmaceuticals Completes Acquisition of Novitium Pharma, Significantly Enhancing R&D; Capabilities and Scale of Generics and CDMO Businesses
- Ampersand Invests in Alliance Pharma, Leading Bioanalytical CRO
- Leinco Technologies Receives Growth Equity Investment From Ampersand Capital Partners
- Proposed Acquisition of Life Sciences manufacturer Adaptas Solutions for $271m
- ANI Pharmaceuticals Announces FDA Approval of Purified Cortrophin™ Gel for Multiple Indications Including Multiple Sclerosis, Rheumatoid Arthritis and Nephrotic Syndrome
- Tjoapack expands into the US with the acquisition of Pharma Packaging Solutions
- Arranta Bio Announces First End-to-End Manufacturing for mRNA Vaccines in its Commercial-ready GMP Facility
- Precision Coating Announces Merger with N2 Biomedical to Expand Medical Coatings Platform
- Curia to Acquire US-based LakePharma, Expanding End-to-End R&D Capabilities and Scale for Biologics
- Bioventus and Misonix Announce Definitive Agreement for Bioventus to Acquire Misonix
- Protagen Protein Services Merges with GeneWerk to Integrate Leading Protein and Gene Therapy Analytic Platforms
- Nexelis acquires the GSK vaccines clinical bioanalytical laboratory located in Marburg – Germany and enters into a 5-year strategic agreement with GSK
- Vibalogics Expands Manufacturing Capacity
- Genezen Strengthens Leadership with New Board Appointments
- Confluent Medical Technologies Expanding, Adding Capacity for Nitinol Processing and Catheter Manufacturing
- PerkinElmer Expands Cell Biology Leadership with Agreement to Acquire Nexcelom Bioscience
- MedPharm Announces Expansion of Formulation Development and Analytical Service Labs in the UK
- Confluent Medical Announces Strategic Investment in The Electrospinning Company
- Nexelis and JOINN Laboratories sign Letter of Intent entering partnership to support international sponsors in China in the bioanalytical field
- Bioventus Acquires Bioness, Inc.
- Ampersand Invests in Magritek, Leading Supplier of Benchtop NMR Instruments
- ANI Pharmaceuticals to Acquire Novitium Pharma, Strengthening R&D; Engine and Expanding Generics and CDMO Business
- Curia Completes Acquisition of LakePharma
- Arranta Bio Announces Addition of 130,000 sq. ft. Boxborough, Mass., Manufacturing Facility to Supply Clinical and Commercial Microbiome Products for Clients and closes Series B Equity Financing
- Bioventus Announces Pricing of Initial Public Offering
- Arranta Bio announces key leadership additions of Chief Operations Officer and SVP of Business Development as it commits to a $100M investment in building end-to-end microbiome capacity
- Ampersand Completes Sale of Portfolio Company Nexcelom Bioscience to PerkinElmer
- Announcing vivitide, a New Name With Continuous Commitment to Science Based on Long Experience in the World of Peptides and Antibodies
- Genezen Laboratories Receives Growth Equity Investment from Ampersand Capital Partners
- Adaptas Solutions Acquires Cadence Fluidics
- N2 Biomedical Appoints Eric Tobin To Chief Executive Officer
- Ampersand Capital Partners Establishes Portfolio Acceleration Team
- Ampersand Announced Today the $670 Million Closing of the Ampersand Continuation Fund (“AMP-CF”) with Confluent Medical Technologies as Core Asset
- With new CEO on board, Germany’s Vibalogics lays out $150M for Boston viral vector site
- StageBio Expands Its Global Presence With Acquisition of TPL Path Labs
- GeneWerk GmbH Announces Growth Equity Investment from Ampersand Capital Partners
- Ampersand Capital Partners Acquires American Laboratory Products Company
- Bruker Announces Acquisition of Canopy Biosciences, LLC
- StageBio Announces Opening of New Facility in Greater Boston Area
- Nexelis Acquires Integrated Bioanalytical CRO AIT Bioscience
- Key Biologics and Astarte Biologics Rebrand as Cellero and Announce Completion of Phase One of $50 Million Multi-Year Expansion Plan
- Tjoapack receives Investment from Ampersand Capital Partners
- Ampersand Closes Oversubscribed Fund at $690 Million Hard Cap
- Nexelis to Acquire Specialty Immunogenicity and Immune-Oncology Testing Laboratory ImmunXperts
- Adaptas Solutions to Acquire Applied Kilovolts and Analytical Instrumentation Business from L3Harris Technologies
- Alcami Expands its Sterile Fill-Finish Capacity with Acquisition of TriPharm Services
- Interpace Biosciences Enters into Agreement for $20 Million Investment from 1315 Capital and Ampersand Capital Partners
- Ampersand Capital Partners Acquires Peptides International And Merges Company With New England Peptide
- Canopy Biosciences Acquires Core Diagnostics
- Arranta Bio announces the acquisition of Captozyme™, creating a Center of Excellence for microbiome development and clinical supply
- StageBio and Alizée Pathology Merge
- Mesa Labs acquires Gyros Protein Technologies
- Arranta Bio announces $82M in new funding, and a strategic partnership with Thermo Fisher Scientific
- Interpace Announces Closing of $13 Million Second Tranche Acquisition Financing from Ampersand Capital Partners
- New England Peptide Receives Growth Equity Investment From Ampersand Capital Partners
- N2 Biomedical Appoints Victor Nunes and Dean Schauer to Board of Directors
- Interpace Diagnostics Acquires Cancer Genetics’ Biopharma Services Business Supported by Investment from Ampersand Capital Partners
- Ampersand Completes Growth Equity Investment In N2 Biomedical
- NEOMED-LABS / Pacific Biomarkers Strengthens its Immunology Franchise by Acquiring PAIRimmune
- Ampersand Capital Partners completes Growth Equity Investment in Transplantation Diagnostic firm GenDx
- StageBio and Tox Path Specialists Merge
- Canopy Biosciences Acquires Zellkraftwerk GmbH
- Ampersand Capital Partners to Acquire Vibalogics GmbH
- Timothy McGrath Appointed Chief Operating Officer of Newly Merged NEOMED-LABS / Pacific Biomarkers
- Thermo Fisher Scientific to Acquire Brammer Bio, a Leader in Viral Vector Manufacturing
- HSRL and VPS Announce New Brand: StageBio
- Confluent Medical Technologies Launches the High-Performance Nitinol Tubing Center of Excellence; Acquires Tube Hollows International (THI) to Now Offer the Most Comprehensive Selection of Nitinol Tubing for High-Performance Implants
- Ampersand Capital Partners Acquires Pacific Biomarkers and Merges Company with NEOMED-LABS
- Detector Technology Acquires ETP Ion Detect
- GENEWIZ to be Acquired by Brooks Automation for $450 Million
- Brammer Bio announces progress on $200 million program to advance gene therapies
- Key Biologics and Blood Centers of America Partner to Advance Cell Therapy and Regenerative Medicine
- Key Biologics and Astarte Biologics Merge
- Sarepta Therapeutics Enters into Long-term Strategic Manufacturing Partnership with Brammer Bio to Support Gene Therapy Development and Commercial Supply
- MolecularMD and Genoptix Enter into a Definitive Agreement to Market the MRDx® BCR-ABL Test, a Companion Diagnostic for Treatment-free Remission in Ph+ CML-CP Patients Treated with Tasigna®
- LakePharma Appoints David Boyle to Chief Financial Officer
- MedPharm Receives Growth Equity Investment from Ampersand Capital Partners
- Brammer Bio Expands Leadership Team for Commercial Readiness
- Nexcelom Bioscience announces strategic growth investment from Ampersand Capital Partners
- Ampersand Closes Oversubscribed Fund at $450 Million Hard Cap
- Genoptix Completes Acquisition of PersonalizeDx from Rosetta Genomics
- Detector Technology, Inc. Acquires Scientific Instrument Services
- LakePharma Announces Expansion And New MicroBiomanufacturing Center In Hopkinton, MA
- CutisPharma Announces FDA Approval Of FIRVANQ™ For Treatment Of Clostridium Difficile Associated Diarrhea (CDAD) And Staphylococcus Aureus Colitis
- Avista Pharma Solutions Acquires Solid Form Solutions
- Detector Technology, Inc. Secures Growth Equity Investment from Ampersand Capital Partners
- Genoptix to Acquire Rosetta Genomics for $10 Million in Cash
- Lakepharma Raises Growth Capital From Summit Partners And Ampersand Capital Partners
- Brammer Bio Launches Gene Therapy Product Manufacturing Operations in Massachusetts
- GENEWIZ Honored with Two Top New Jersey Business Awards
- Avista Pharma Solutions Expands Drug Product cGMP Manufacturing at Colorado Site
- Brammer Bio is Awarded MassEcon Impact Award
- Gyros Protein Technologies Signs Distribution Agreement With Euro Diagnostica
- Brammer Bio Expands Cell and Gene Therapy Capacity in Florida and Massachusetts, Partnering with Pall Life Sciences for Suspension and Adherent Platform Technologies
- LakePharma Expands into New Facility in South San Francisco, California
- Bioventus Receives US FDA Approval for DUROLANE
- CutisPharma Announces Executive Team And Board Appointments
- Genoptix’s Immuno-Oncology Testing Now Covers Additional Tumor Types
- Balchem Corporation Acquires Innovative Food Processors, Inc.
- Brammer Bio Announces Major Milestone in Establishing Commercial-ready Gene Therapy Supply for the Industry
- Ampersand Completes Growth Equity Investment In Corpus Medical